A
Agilent Technologies, Inc.
A's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over A overall, supported by stronger modeled upside and stronger valuation.
A Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Strong | |
| Healthy |
A's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
A PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 26x | $173 | — |
| Cheap | 28x | $141 | -19% |
| Fair | 31x | $160 | -7.6% |
| Current | 34x | $173 | — |
| Expensive | 45x | $227 | +31% |
Historical ranges are pointers, not guarantees.
A has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
A Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for A, with profitability improving.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
A Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $6.70 | +32% |
| Q3 2026 | $5.08 | +19% |
| Q2 2026 | $4.98 | +23% |
| Q1 2026 | $4.53 | +3.9% |
| Q4 2025 | $4.57 | +3.2% |
| Q3 2025 | $4.27 | -11% |
| Q2 2025 | $4.06 | -3.6% |
| Q1 2025 | $4.36 | +4.3% |
| Q4 2024 | $4.43 | +5.7% |
A earned $5.08 per share over the past year, up 19% from the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.83 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over A on earnings, with more consistent year-over-year improvement.
A Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.9B | +8.1% |
| Q2 2026 | $1.8B | +10% |
| Q1 2026 | $1.8B | +7% |
| Q4 2025 | $1.9B | +9.4% |
| Q3 2025 | $1.7B | +10% |
| Q2 2025 | $1.7B | +6% |
| Q1 2025 | $1.7B | +1.4% |
| Q4 2024 | $1.7B | +0.8% |
A's revenue has grown year over year for eight quarters in a row: $1.9B last quarter, up 8.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 24% | +2.9 points |
| Q2 2026 | 22% | +3.8 points |
| Q1 2026 | 20% | -2.7 points |
| Q4 2025 | 24% | -0.2 points |
| Q3 2025 | 21% | -0.4 points |
| Q2 2025 | 18% | -5.1 points |
| Q1 2025 | 22% | -0.8 points |
| Q4 2024 | 24% | -0.2 points |
A's operating margin was 24% last quarter, up 2.9 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over A on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over A on profitability, with a higher operating margin.
A Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $439M | +69% |
| Q2 2026 | $201M | +88% |
| Q1 2026 | $175M | -48% |
| Q4 2025 | $452M | +16% |
| Q3 2025 | $259M | -28% |
| Q2 2025 | $107M | -53% |
| Q1 2025 | $334M | -15% |
| Q4 2024 | $388M | -10% |
A generated $1.3B in free cash flow over the past year, up 16% from the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over A on cash flow, with more consistent year-over-year improvement.
A Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | -0.7% | -2M shares |
| 3 years | -4.1% | -12M shares |
| 5 years | -7.5% | -23M shares |
| Available history | -11% | -35M shares |
A has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $78M |
| Q2 2026 | $65M |
| Q1 2026 | $152M |
| Q4 2025 | $85M |
| Q3 2025 | $85M |
| Q2 2025 | $165M |
| Q1 2025 | $90M |
| Q4 2024 | $335M |
A spent $380M buying back its own shares over the past year, down 44% from the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
A Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 0.8x | Very low |
| Q1 2026 | 0.9x | Very low |
| Q4 2025 | 0.9x | Very low |
| Q3 2025 | 1.1x | Healthy |
| Q2 2025 | 1.2x | Healthy |
| Q1 2025 | 1.1x | Healthy |
| Q4 2024 | 1.2x | Healthy |
A has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
A Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 67.7 | Neutral |
| Stochastic | 80.4 | Overbought |
A's weekly RSI is 68 (neutral) and its Stochastic is 80 (overbought).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
A PE vs Healthcare Sector
| Metric | A | Sector median | Relative |
|---|---|---|---|
| PE | 34x | 26x | 32% above |
| PE % | 65 | 29 | 36 pts above |
A has the edge over LLY on valuation relative to its sector.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
A Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $172.5 | 0.3% above |
| 20 week MA | $155.7 | 11% above |
| 50 week MA | $138.1 | 25% above |
| 100 week MA | $132.5 | 31% above |
| 200 week MA | $132.5 | 31% above |
A has climbed back above all five of its weekly moving averages, and it's now 31% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
A Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $85.4 | $117.3 | +37% |
| 2021 | $117.3 | $157.8 | +35% |
| 2022 | $157.8 | $149.2 | -5.4% |
| 2023 | $149.2 | $139.0 | -6.8% |
| 2024 | $139.0 | $135.5 | -2.5% |
| 2025 | $135.5 | $138.4 | +2.1% |
| 2026 YTD | $138.4 | $173.0 | +25% |
A has finished lower in three of the last six years. It's up 25% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over A on returns for 2026, with the stronger performance.